Diranersen

Diranersen
Clinical data
Other namesBIIB-080; BIIB080; IONIS-MAPTRx; ISIS-814907
Routes of
administration
Intrathecal injection[1]
Drug classAntisense oligonucleotide against tau
Identifiers
CAS Number
PubChem SID
UNII

Diranersen (INNTooltip International Nonproprietary Name; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease.[1][2][3][4] It is given by intrathecal injection.[1] The drug is under development by Ionis Pharmaceuticals and Biogen.[1][2][3] As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease.[1][2][3] Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65%[3][4] and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial.[4][5] This degree of slowing is on par with that of existing anti-amyloid antibodies.[5] The drug is one of the most clinically advanced anti-tau drugs under development.[6]

See also

References

  1. ^ a b c d e "Diranersen". AdisInsight. 2 July 2026. Retrieved 19 July 2026.
  2. ^ a b c "Delving into the Latest Updates on ISIS-814907 with Synapse". Synapse. 20 June 2026. Retrieved 19 July 2026.
  3. ^ a b c d "Diranersen". ALZFORUM. 14 May 2026. Retrieved 19 July 2026.
  4. ^ a b c Mackenzie RJ (14 July 2026). "A new sort of Alzheimer's drug shows glimmers of promise". Science News. Retrieved 19 July 2026.
  5. ^ a b Joseph A (14 July 2026). "Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows". STAT. Retrieved 19 July 2026.
  6. ^ Incorvaia D (14 July 2026). "Biogen defends anti-tau drug after stock slides on Alzheimer's readout". Fierce Biotech. Retrieved 19 July 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.